Radius CEO: Osteoporosis Drug on Track Despite Skittish Stock
( 02:50 )
ADD TO MY LIST
REMOVE FROM MY LIST

70 views

VIDEO DESCRIPTION:

The recent volatility surrounding Radius Health shares should lessen as the market starts focusing on its osteoporosis drug Abaloparatide, said the company's CEO Robert Ward. Radius Health sold 6.5 million shares of stock $8 a share in a June IPO, raising $52 million.

ADD TO MY LIST
REMOVE FROM MY LIST
ADD TO MY LIST
REMOVE FROM MY LIST
Add to My List Remove from My List

Added to My List

Removed from My List

Did you know?
By signing up, you can access your watch list and history across your other devices including mobile, tablet and Connected TV.
You can

It only takes a few seconds!

Did you know?
By signing up, you can access your watch list and history across your other devices including mobile, tablet and Connected TV.
You can

It only takes a few seconds!